Corey Lyon
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Physicians, Family | 2 | 2022 | 242 | 1.280 |
Why?
| Osteoarthritis, Knee | 2 | 2018 | 224 | 1.030 |
Why?
| Uterine Cervical Neoplasms | 2 | 2020 | 215 | 0.930 |
Why?
| Glucocorticoids | 3 | 2018 | 554 | 0.930 |
Why?
| Medical Staff | 2 | 2022 | 16 | 0.910 |
Why?
| Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 66 | 0.910 |
Why?
| Papillomavirus Infections | 2 | 2020 | 267 | 0.890 |
Why?
| Hypertension | 3 | 2021 | 1243 | 0.860 |
Why?
| Metformin | 2 | 2023 | 303 | 0.830 |
Why?
| Sphygmomanometers | 1 | 2021 | 7 | 0.810 |
Why?
| Insulin, Isophane | 1 | 2021 | 16 | 0.800 |
Why?
| Automation | 1 | 2021 | 79 | 0.790 |
Why?
| Insulin Glargine | 1 | 2021 | 70 | 0.780 |
Why?
| Employment | 1 | 2022 | 142 | 0.770 |
Why?
| Early Detection of Cancer | 2 | 2022 | 363 | 0.770 |
Why?
| Analgesia, Obstetrical | 1 | 2020 | 12 | 0.750 |
Why?
| Prediabetic State | 1 | 2023 | 234 | 0.750 |
Why?
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 1263 | 0.750 |
Why?
| Blood Pressure Determination | 1 | 2021 | 135 | 0.750 |
Why?
| Aspirin | 2 | 2020 | 343 | 0.750 |
Why?
| Analgesia, Epidural | 1 | 2020 | 20 | 0.740 |
Why?
| Preventive Health Services | 1 | 2022 | 144 | 0.740 |
Why?
| Post-Concussion Syndrome | 1 | 2023 | 137 | 0.740 |
Why?
| Anti-Bacterial Agents | 2 | 2021 | 1560 | 0.730 |
Why?
| Ganglion Cysts | 1 | 2020 | 10 | 0.730 |
Why?
| Papillomaviridae | 1 | 2020 | 102 | 0.720 |
Why?
| Humans | 52 | 2023 | 122414 | 0.720 |
Why?
| C-Reactive Protein | 2 | 2021 | 362 | 0.720 |
Why?
| Wrist | 1 | 2020 | 57 | 0.700 |
Why?
| Spironolactone | 1 | 2019 | 38 | 0.690 |
Why?
| Diuretics | 1 | 2019 | 78 | 0.680 |
Why?
| Diabetes Mellitus, Type 2 | 4 | 2022 | 2207 | 0.680 |
Why?
| Ketorolac | 1 | 2019 | 19 | 0.680 |
Why?
| Memory | 1 | 2021 | 241 | 0.680 |
Why?
| Probiotics | 1 | 2019 | 52 | 0.670 |
Why?
| Glucosamine | 1 | 2018 | 12 | 0.670 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 301 | 0.660 |
Why?
| Erythromycin | 1 | 2018 | 26 | 0.660 |
Why?
| Rh-Hr Blood-Group System | 1 | 2018 | 12 | 0.660 |
Why?
| Acute Pain | 1 | 2019 | 32 | 0.650 |
Why?
| Sweating | 1 | 2018 | 24 | 0.640 |
Why?
| Glycemic Index | 1 | 2018 | 24 | 0.640 |
Why?
| Viscosupplements | 1 | 2018 | 10 | 0.640 |
Why?
| Ureteral Calculi | 1 | 2018 | 13 | 0.640 |
Why?
| Hot Flashes | 1 | 2018 | 72 | 0.610 |
Why?
| Antibiotic Prophylaxis | 1 | 2018 | 101 | 0.610 |
Why?
| Testosterone | 1 | 2021 | 353 | 0.600 |
Why?
| Musculoskeletal System | 1 | 2018 | 56 | 0.600 |
Why?
| Patient Education as Topic | 2 | 2022 | 717 | 0.590 |
Why?
| Obstetric Labor, Premature | 1 | 2017 | 41 | 0.590 |
Why?
| Labor, Obstetric | 1 | 2017 | 54 | 0.580 |
Why?
| Telemedicine | 2 | 2022 | 686 | 0.580 |
Why?
| Prenatal Diagnosis | 1 | 2018 | 171 | 0.580 |
Why?
| Warfarin | 1 | 2017 | 147 | 0.570 |
Why?
| Hypoglycemia | 1 | 2021 | 406 | 0.570 |
Why?
| Factor Xa Inhibitors | 1 | 2017 | 141 | 0.570 |
Why?
| Analgesics | 1 | 2018 | 163 | 0.570 |
Why?
| Job Satisfaction | 1 | 2018 | 175 | 0.560 |
Why?
| Randomized Controlled Trials as Topic | 7 | 2023 | 1256 | 0.560 |
Why?
| Migraine Disorders | 1 | 2017 | 81 | 0.560 |
Why?
| Melatonin | 1 | 2017 | 110 | 0.560 |
Why?
| Athletic Injuries | 1 | 2023 | 499 | 0.560 |
Why?
| Family Practice | 2 | 2018 | 485 | 0.560 |
Why?
| Hyaluronic Acid | 1 | 2018 | 199 | 0.550 |
Why?
| Carpal Tunnel Syndrome | 1 | 2016 | 28 | 0.550 |
Why?
| Brain Concussion | 1 | 2023 | 470 | 0.550 |
Why?
| Respiratory Distress Syndrome, Newborn | 1 | 2017 | 107 | 0.540 |
Why?
| Methylprednisolone | 1 | 2016 | 86 | 0.540 |
Why?
| Practice Guidelines as Topic | 4 | 2020 | 1518 | 0.540 |
Why?
| Acute Coronary Syndrome | 1 | 2019 | 268 | 0.530 |
Why?
| Menopause | 1 | 2018 | 269 | 0.520 |
Why?
| Colorectal Neoplasms | 1 | 2022 | 645 | 0.510 |
Why?
| Cough | 1 | 2015 | 104 | 0.490 |
Why?
| Patient Care Team | 2 | 2018 | 520 | 0.490 |
Why?
| Mass Screening | 2 | 2022 | 1094 | 0.490 |
Why?
| Exercise Therapy | 1 | 2018 | 374 | 0.480 |
Why?
| Respiratory Tract Diseases | 1 | 2015 | 140 | 0.470 |
Why?
| Adrenal Cortex Hormones | 1 | 2017 | 515 | 0.450 |
Why?
| Acupuncture Therapy | 2 | 2023 | 19 | 0.450 |
Why?
| Antioxidants | 1 | 2017 | 579 | 0.450 |
Why?
| Myofascial Pain Syndromes | 2 | 2023 | 17 | 0.450 |
Why?
| Anticoagulants | 1 | 2017 | 589 | 0.440 |
Why?
| Virus Diseases | 1 | 2015 | 200 | 0.440 |
Why?
| Atrial Fibrillation | 1 | 2017 | 392 | 0.440 |
Why?
| Behavior Therapy | 3 | 2023 | 249 | 0.430 |
Why?
| Low Back Pain | 2 | 2023 | 103 | 0.410 |
Why?
| Health Promotion | 1 | 2018 | 707 | 0.400 |
Why?
| Cardiovascular Diseases | 2 | 2020 | 1858 | 0.390 |
Why?
| Aged, 80 and over | 7 | 2021 | 6831 | 0.380 |
Why?
| Pain Measurement | 4 | 2023 | 479 | 0.370 |
Why?
| Aged | 10 | 2021 | 20448 | 0.340 |
Why?
| Depression | 1 | 2017 | 1189 | 0.330 |
Why?
| Female | 16 | 2023 | 63418 | 0.320 |
Why?
| Fatty Acids, Omega-3 | 2 | 2020 | 127 | 0.320 |
Why?
| Papillomavirus Vaccines | 1 | 2010 | 221 | 0.310 |
Why?
| Pregnancy | 4 | 2022 | 5810 | 0.310 |
Why?
| Organizational Innovation | 2 | 2019 | 141 | 0.300 |
Why?
| Middle Aged | 11 | 2021 | 28497 | 0.300 |
Why?
| Abdomen, Acute | 1 | 2006 | 20 | 0.300 |
Why?
| Azithromycin | 2 | 2018 | 94 | 0.290 |
Why?
| Treatment Outcome | 7 | 2021 | 9673 | 0.280 |
Why?
| Enuresis | 1 | 2005 | 5 | 0.280 |
Why?
| Renal Agents | 1 | 2005 | 5 | 0.280 |
Why?
| Deamino Arginine Vasopressin | 1 | 2005 | 11 | 0.280 |
Why?
| Adult | 8 | 2021 | 32302 | 0.250 |
Why?
| Hormone Replacement Therapy | 2 | 2023 | 80 | 0.240 |
Why?
| Fibromyalgia | 1 | 2023 | 58 | 0.230 |
Why?
| Naltrexone | 1 | 2023 | 76 | 0.220 |
Why?
| Age Factors | 2 | 2022 | 3110 | 0.220 |
Why?
| Electronics | 1 | 2023 | 79 | 0.220 |
Why?
| Occult Blood | 1 | 2022 | 27 | 0.210 |
Why?
| Dose-Response Relationship, Drug | 3 | 2019 | 1981 | 0.210 |
Why?
| Evidence-Based Medicine | 4 | 2019 | 730 | 0.210 |
Why?
| Lipid Regulating Agents | 1 | 2020 | 2 | 0.200 |
Why?
| Life Style | 1 | 2023 | 436 | 0.200 |
Why?
| Postmenopause | 1 | 2023 | 307 | 0.200 |
Why?
| Fish Oils | 1 | 2020 | 26 | 0.200 |
Why?
| Hypertriglyceridemia | 1 | 2020 | 39 | 0.190 |
Why?
| Labor Stage, Second | 1 | 2020 | 4 | 0.190 |
Why?
| Time Factors | 2 | 2023 | 6660 | 0.190 |
Why?
| United States | 4 | 2022 | 13259 | 0.190 |
Why?
| Prenatal Care | 1 | 2022 | 257 | 0.190 |
Why?
| Colonoscopy | 1 | 2022 | 208 | 0.180 |
Why?
| Carcinoma, Basal Cell | 1 | 2020 | 77 | 0.180 |
Why?
| Pain Management | 2 | 2023 | 305 | 0.170 |
Why?
| Delivery, Obstetric | 1 | 2020 | 128 | 0.170 |
Why?
| Male | 9 | 2021 | 59516 | 0.170 |
Why?
| Systems Integration | 1 | 2018 | 42 | 0.170 |
Why?
| Ticlopidine | 1 | 2019 | 71 | 0.170 |
Why?
| Rho(D) Immune Globulin | 1 | 2018 | 3 | 0.170 |
Why?
| Chondroitin Sulfates | 1 | 2018 | 35 | 0.160 |
Why?
| Primary Health Care | 2 | 2019 | 1624 | 0.160 |
Why?
| Cognitive Dysfunction | 1 | 2023 | 309 | 0.160 |
Why?
| Clostridium Infections | 1 | 2019 | 60 | 0.160 |
Why?
| Venlafaxine Hydrochloride | 1 | 2018 | 12 | 0.160 |
Why?
| Netherlands | 1 | 2018 | 74 | 0.160 |
Why?
| Proton Pump Inhibitors | 1 | 2019 | 102 | 0.160 |
Why?
| Citalopram | 1 | 2018 | 28 | 0.160 |
Why?
| Visual Analog Scale | 1 | 2018 | 34 | 0.160 |
Why?
| Antidepressive Agents, Second-Generation | 1 | 2018 | 37 | 0.160 |
Why?
| Arthralgia | 1 | 2018 | 56 | 0.160 |
Why?
| Yoga | 1 | 2018 | 29 | 0.160 |
Why?
| Pneumonia, Bacterial | 1 | 2019 | 113 | 0.160 |
Why?
| Primary Prevention | 1 | 2020 | 211 | 0.160 |
Why?
| Injections, Intra-Articular | 1 | 2018 | 63 | 0.160 |
Why?
| Patients | 1 | 2019 | 176 | 0.160 |
Why?
| Community-Acquired Infections | 1 | 2019 | 148 | 0.150 |
Why?
| Estrogen Replacement Therapy | 1 | 2018 | 117 | 0.150 |
Why?
| Prurigo | 1 | 2016 | 2 | 0.150 |
Why?
| Dietary Supplements | 1 | 2020 | 472 | 0.150 |
Why?
| Sulfonylurea Compounds | 1 | 2017 | 43 | 0.150 |
Why?
| Recurrence | 1 | 2020 | 997 | 0.150 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 44 | 0.140 |
Why?
| Regression Analysis | 1 | 2019 | 1017 | 0.140 |
Why?
| Nonprescription Drugs | 1 | 2017 | 69 | 0.140 |
Why?
| Pain | 2 | 2023 | 744 | 0.140 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 410 | 0.140 |
Why?
| Gastroesophageal Reflux | 1 | 2019 | 252 | 0.140 |
Why?
| Sleep | 1 | 2022 | 722 | 0.140 |
Why?
| Burnout, Professional | 2 | 2019 | 332 | 0.140 |
Why?
| Exanthema | 1 | 2016 | 78 | 0.140 |
Why?
| Prednisone | 1 | 2016 | 234 | 0.140 |
Why?
| Hemorrhage | 1 | 2020 | 663 | 0.130 |
Why?
| Administration, Oral | 1 | 2018 | 784 | 0.130 |
Why?
| Injections | 1 | 2016 | 170 | 0.130 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2019 | 425 | 0.130 |
Why?
| Psychiatry | 1 | 2018 | 205 | 0.130 |
Why?
| Acute Disease | 1 | 2018 | 983 | 0.130 |
Why?
| Health Status | 1 | 2020 | 758 | 0.130 |
Why?
| Achilles Tendon | 1 | 2015 | 49 | 0.130 |
Why?
| Diabetic Foot | 1 | 2015 | 55 | 0.130 |
Why?
| Young Adult | 2 | 2023 | 11063 | 0.120 |
Why?
| Quality of Health Care | 1 | 2019 | 629 | 0.120 |
Why?
| Sulfonamides | 1 | 2018 | 455 | 0.120 |
Why?
| Tendon Injuries | 1 | 2015 | 81 | 0.120 |
Why?
| Pandemics | 1 | 2022 | 1397 | 0.120 |
Why?
| Double-Blind Method | 1 | 2018 | 1702 | 0.120 |
Why?
| Gestational Age | 1 | 2017 | 784 | 0.120 |
Why?
| Treatment Failure | 1 | 2015 | 348 | 0.120 |
Why?
| Venous Thromboembolism | 1 | 2017 | 239 | 0.120 |
Why?
| Drug Therapy, Combination | 1 | 2017 | 988 | 0.120 |
Why?
| Osteomyelitis | 1 | 2015 | 110 | 0.120 |
Why?
| Psychometrics | 1 | 2017 | 672 | 0.120 |
Why?
| Administration, Inhalation | 1 | 2015 | 664 | 0.110 |
Why?
| Skin Neoplasms | 1 | 2020 | 841 | 0.110 |
Why?
| Colorado | 2 | 2019 | 4319 | 0.100 |
Why?
| Alphapapillomavirus | 1 | 2010 | 38 | 0.100 |
Why?
| Mental Disorders | 1 | 2018 | 951 | 0.090 |
Why?
| Hypoglycemic Agents | 1 | 2017 | 1053 | 0.090 |
Why?
| Emergency Service, Hospital | 1 | 2019 | 1920 | 0.080 |
Why?
| Prospective Studies | 1 | 2018 | 6687 | 0.070 |
Why?
| Surveys and Questionnaires | 1 | 2017 | 4878 | 0.070 |
Why?
| Adolescent | 1 | 2023 | 18913 | 0.060 |
Why?
| Diagnostic Imaging | 1 | 2006 | 309 | 0.060 |
Why?
| Amitriptyline | 1 | 2023 | 24 | 0.060 |
Why?
| Magnetic Resonance Imaging | 1 | 2015 | 3263 | 0.060 |
Why?
| Trigger Points | 1 | 2023 | 15 | 0.060 |
Why?
| Diagnosis, Differential | 1 | 2006 | 1420 | 0.050 |
Why?
| Dermoscopy | 1 | 2020 | 13 | 0.050 |
Why?
| Clinical Trials as Topic | 1 | 2005 | 984 | 0.050 |
Why?
| Long-Term Care | 1 | 2019 | 73 | 0.040 |
Why?
| Models, Organizational | 1 | 2019 | 144 | 0.040 |
Why?
| Workflow | 1 | 2018 | 148 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2018 | 195 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 757 | 0.040 |
Why?
| Skin | 1 | 2020 | 693 | 0.030 |
Why?
| Blood Sedimentation | 1 | 2015 | 34 | 0.030 |
Why?
| Survival Analysis | 1 | 2019 | 1321 | 0.030 |
Why?
| Rupture | 1 | 2015 | 106 | 0.030 |
Why?
| Mental Health Services | 1 | 2018 | 329 | 0.030 |
Why?
| Child | 2 | 2022 | 19530 | 0.030 |
Why?
| Foot | 1 | 2015 | 124 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2016 | 573 | 0.030 |
Why?
| Comorbidity | 1 | 2018 | 1599 | 0.030 |
Why?
| Blood Glucose | 1 | 2022 | 1956 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 2438 | 0.030 |
Why?
| Radiography | 1 | 2015 | 886 | 0.030 |
Why?
| Prognosis | 1 | 2019 | 3555 | 0.020 |
Why?
| Quality Improvement | 1 | 2018 | 998 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2015 | 1854 | 0.020 |
Why?
| Blood Pressure | 1 | 2016 | 1709 | 0.020 |
Why?
| Risk Assessment | 1 | 2019 | 3211 | 0.020 |
Why?
| Infant | 1 | 2022 | 8511 | 0.020 |
Why?
| Risk Factors | 1 | 2017 | 9343 | 0.010 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|